Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy
This trial has been completed.
|Sponsor||University of California, Irvine|
|Collaborator||Copan Diagnostics, Inc.|
|Start date||October 2008|
|End date||June 2014|
|Trial size||136 participants|
|Trial identifier||NCT00915213, 2008-6418|
The purpose of this study is to discover how often certain bacteria are found in the rectum at the time of a prostate needle biopsy to diagnose prostate cancer. Certain bacteria are of importance because they can cause serious infection. Antibiotics that urologists commonly use to prevent these bacteria from causing infection are no longer effective. Many physicians around the world are noting increased infections with antibiotic resistant bacteria. Therefore; despite treating patients who are to undergo prostate biopsy with antibiotics, certain patients are being readmitted to the hospital with a serious infection. In order to study the incidence of these particular bacteria, the best method is to culture the bacteria at the time of the biopsy. This involves one rectal culture swab just prior to needle biopsy of the prostate. Once the incidence of these bacteria is known we may take steps to prevent the serious infections that occur as a result of prostate biopsy.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
Men who undergo repeat prostate biopsy
Male participants at least 18 years old.
Inclusion Criteria: - adult males - repeat prostate biopsy Exclusion Criteria: - first time prostate biopsy - minors
|Official title||Incidence of Fluoroquinolone Resistant Enterobacteraciae in Patients Undergoing Repeat Ultrasound Guided Prostate Biopsy|
|Principal investigator||Atreya Dash, MD|
Call for more information